Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Rahul Aggarwal, ESMO 2021: Ceralasertib in ARID1A-deficient and ARID1A-intact Advanced Solid Tumour Malignancies

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 11th 2021

touchONCOLOGY joins Prof Rahul Aggarwal (UCSF School of Medicine, San Francisco, CA, USA), to discuss the interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumour malignancies.

Questions
1. Could you tell us a little about ARID1A alterations in solid tumours and potential therapeutic targets in ARID1A-mutated tumours? (00:15-01:12)
2. What is the rationale for the use of ceralasertib in patients harbouring ARID1A-deficient solid tumours? (01:12-02:10)
3. What were the aims and design of the study you are presenting? (02:10-03:20)
4. How well were the clinical endpoints achieved? (03:20-04:10)
5. What will stage 2 of the study entail and which patients will be eligible? (04:10-04:45)

Disclosures: UCSF School of Medicine has received research funding from AstraZeneca.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed in coverage of the ESMO 2021 Annual Meeting.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup